Pulmatrix and Eos SENOLYTIX Unite to Revolutionize Mitochondrial Therapies for Healthspan Improvement Pulmatrix and Eos SENOLYTIX have announced a merger to become a leader in gerotherapeutics, focusing on novel therapies for aging-related diseases. The goal is to enhance healthspan through mitochondrial-focused treatments.

Pulmatrix and Eos SENOLYTIX Unite to Revolutionize Mitochondrial Therapies for Healthspan Improvement #United_States #Pulmatrix #Framingham,_Massachusetts #Eos_SENOLYTIX #PTC-2105